Gastrointestinal Cancers

Patients with locally advanced rectal cancer treated with FOLFOX before surgery had similar outcomes and side effect profiles to those treated with presurgical pelvic chemoradiation.

The Food and Drug Administration granted a priority review for fruquintinib for patients with pretreated metastatic colorectal cancer.

States that expanded Medicaid had improved survival rates in patients with pancreatic and gastric cancers, with greater improvements in Black patients for some analyses.

The drug combination of Lonsurf plus Avastin improved survival in patients with pretreated, metastatic, refractory colorectal cancer, according to recently published study findings.

After being no evidence of disease for about a year and a half, I am now fearing that I’m not fearing enough.

Tislelizumab was found to improve overall survival among patients with advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.

From composer Ryuichi Sakamoto’s death to the “King of Chemo” cycling across the United States to raise funds for mental health and cancer charities, here’s what’s happening in the oncology space this week.

If approved by the FDA, Keytruda plus chemotherapy could provide a frontline therapy for patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

Researchers conducting the VISTA-101 study will assess the safety and efficacy of KVA12123 alone and with Keytruda, in addition to determining the recommended dose of the therapy.

The Food and Drug Administration approved Keytruda for adult and pediatric patients with previously treated unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors.

From Sam Neill announcing his cancer diagnosis to Martina Navratilova stating that she is now cancer-free, here’s what’s happening in the oncology space this week.

Here’s a look back at the cancer drugs that gained FDA approval in the winter of 2023.

Many well-meaning people wanted to hug me after hearing of my rectal cancer diagnosis, but I’m not a very touchy person. So, loved ones supported me in other ways.

I’ve had three colonoscopies within five years and am still colorectal cancer-free.

The phase 2 DESTINY-PanTumor02 trial included patients with HER2-expressing solid tumors such as bladder, pancreatic and rare tumors.

“In the poker game of life, if you’re dealt a bad set of cards, the best you can do is play them as well as you can,” a cancer survivor said.

Positive results have emerged from a trial testing PIPAC, a procedure used for appendiceal, ovarian, gastric and colon cancers that works by spraying chemotherapy directly onto tumors.

From a contestant on “Queer Eye” dying of cancer to a string of brain cancers in former Philadelphia Phillies players, here’s what’s happening in the oncology space this week.

I’ve had many colonoscopies over the last two decades, so here are my tips for preparing for and going through the procedure.

From Senator Bob Casey undergoing prostate cancer surgery to a man giving away his Superbowl tickets to a good friend with stage 4 cancer, here’s what is happening in the oncology space this week.

The FDA recently approved a combination treatment for patients with previously treated metastatic colorectal cancer with HER2-positive disease determined by biomarker testing.

Patients with gastric cancer who quit smoking and/or drinking after undergoing a gastrectomy tended to have a decreased risk of depression, research showed.

Zolbetuximab plus mFOLFOX6 lengthened the time to progression for patients with CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric/gastroesophageal junction (GEJ) adenocarcinoma.

The multicenter study is evaluating the safety and efficacy of nanrilkefusp alfa combined with Erbitux.

Patients with HER2-low gastric cancer tended to have distinct characteristics compared to those with HER2-negative or -positive disease, warranting more research into this group, research found.

The FDA approved Tukysa plus Herceptin for previously treated patients with HER2-positive metastatic colorectal cancer.

I’ve heard the phrase, “don’t waste your cancer,” as a way to encourage survivors to tell their stories and donate to nonprofits.

The combination met its main goal of progression-free survival and secondary goal of overall survival.

Exercising moderately every week has been linked to improved disease outcomes at any BMI in patients with colorectal cancer.

As part of CURE®’s Heal at Home series, we offer a guide on ostomies following surgery and how patients can best care for their stomas.